Trial Profile

Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics/Pharmacodynamics Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Anakinra
Indications COVID 2019 infections; Respiratory tract infections
Focus Therapeutic Use
Acronyms SCIL-COV19 PK/PD trial; SCIL_COV19

Most Recent Events

27 Apr 2021 Status changed from suspended to discontinued.
12 Oct 2020 Planned End Date changed from 30 Sep 2020 to 31 Dec 2020.
12 Oct 2020 Status changed from active, no longer recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com